1. The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up.
The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. Patients with a negative maximum percent reduction from baseline had a decrease in the size of the target tumor and patients with a positive maximum percent reduction from baseline had an increase in tumor size. A, patients in part 1 of the study are identified by daily dose of bosutinib received (n = 36); 13 (36%) had a maximum decrease in target tumor size and 8 of these received bosutinib 400, 500, or 600 mg/day. B, patients in part 2 of the study are identified by cancer type (n = 67); 13 (19%) had a maximum decrease in target tumor size; 7 patients had NSCLC and 3 each had colorectal and pancreas cancer.
Adil I. Daud et al. Clin Cancer Res 2012;18:
©2012 by American Association for Cancer Research